Temazepam
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Temazepam
Temazepam: Known uses and market status in Canada
Summary
All of the TxGNN model’s candidates for Temazepam (score ≥ 0.99) that can be traced to a source are already known uses. There is therefore currently no new predicted indication for this drug. This page lists the market status in Canada and the known-use groups for reference.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 0 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 00604453 | RESTORIL | Valid | |
| 00604461 | RESTORIL | Valid |
Safety Considerations
- Disease-related cautions (knowledge graph): The TxGNN knowledge graph flags contraindication relationships with the following conditions. These come from graph data, not from label text.
- Psychiatric and neurological: anxiety disorder, neurotic disorder, dysthymic disorder, amnestic disorder, retrograde amnesia
- Substance use: substance-related disorder, substance abuse/dependence
- Respiratory: obstructive sleep apnea syndrome, sleep apnea syndrome, congenital central hypoventilation syndrome, Haddad syndrome
- Organ disease: kidney disease, liver disease, gallbladder disease, pyoureter
- Drug interactions: 100 interactions were identified. Examples from the first 20 listed:
- Major: morphine, liposomal morphine (additive central nervous system and respiratory depression is the expected concern)
- Moderate: bupropion, dronabinol, nabilone, metoclopramide, opium, sibutramine, teduglutide
- Minor: antacids (aluminum hydroxide, calcium carbonate, magaldrate, magnesium oxide, carbonate and hydroxide)
- Literature signals: Rebound insomnia on discontinuation (PMID 2567741), and dependence and abuse concerns with benzodiazepines (PMID 26438969). The guidelines and reviews also stress caution in older adults.
Please refer to the package insert for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.